H
Han Shen
Researcher at University of New South Wales
Publications - 24
Citations - 500
Han Shen is an academic researcher from University of New South Wales. The author has contributed to research in topics: Glioma & Radioresistance. The author has an hindex of 10, co-authored 24 publications receiving 335 citations. Previous affiliations of Han Shen include University of Sydney.
Papers
More filters
Journal ArticleDOI
A Metabolic Shift Favoring Sphingosine 1-Phosphate at the Expense of Ceramide Controls Glioblastoma Angiogenesis
Hazem J. Abuhusain,Azadeh Matin,Qiao Qiao,Han Shen,Nupur Kain,Bryan W. Day,Brett W. Stringer,Benjamin Daniels,Maarit A. Laaksonen,Charlie Teo,Kerrie L. McDonald,Anthony S. Don +11 more
TL;DR: The hypothesis that an altered ceramide/S1P balance is an important feature of human cancers and support the development of SPHK1 inhibitors as antiangiogenic agents for cancer therapy is validated.
Journal ArticleDOI
Sensitization of Glioblastoma Cells to Irradiation by Modulating the Glucose Metabolism
TL;DR: The proof of concept that dichloroacetate can effectively sensitize glioblastoma cells to radiotherapy by modulating the metabolic state of tumor cells is provided.
Journal ArticleDOI
Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas
TL;DR: The potential for repurposing anti-parasitic drugs to abolish tumor hypoxia and induce apoptosis of GSCs is highlighted, as this approach would also help in eradicating the radioresistant glioma stem cells (GSCs) as these predominantly rely on mitochondrial metabolism for survival.
Journal ArticleDOI
Dual-targeting of aberrant glucose metabolism in glioblastoma
Han Shen,Stephanie Decollogne,Pierre J. Dilda,Eric Hau,Eric Hau,Sylvia A. Chung,Peter P. Luk,Philip J. Hogg,Kerrie L. McDonald +8 more
TL;DR: A new light is shed with respect to the dual-targeting of glucose metabolism in GBM cells and the innovative combination of PENAO and DCA shows promise in expanding GBM therapies.
Journal ArticleDOI
Targeting reduced mitochondrial DNA quantity as a therapeutic approach in pediatric high-grade gliomas.
Han Shen,Man Yu,Maria Tsoli,Cecilia Chang,Swapna Joshi,Jie Liu,Scott Ryall,Yevgen Chornenkyy,Robert Siddaway,Cynthia Hawkins,David S. Ziegler,David S. Ziegler +11 more
TL;DR: The results suggest metabolic alterations as an onco-requisite factor of pHGG tumorigenesis and targeting reduced mtDNA quantity represents a promising therapeutic strategy for pHGG.